BioMarin Pharmaceutical Inc. (BMRN) Business Profile

What it does

BioMarin Pharmaceutical develops, manufactures and sells medicines for rare diseases, particularly conditions with a genetic cause. Its customers include specialty pharmacies, hospitals, government agencies and distributors; physicians prescribe its medicines to patients. BioMarin was founded in 1997 and is headquartered in Novato, California. Alexander Hardy is its president and chief executive.

Its skeletal conditions business includes VOXZOGO, a daily injection for children with achondroplasia, a condition that affects bone growth. Its enzyme therapies include VIMIZIM and NAGLAZYME for inherited disorders in which the body lacks enzymes needed to break down certain substances. PALYNZIQ and KUVAN treat phenylketonuria, an inherited metabolic condition.

Other medicines include BRINEURA, infused into the brain to slow loss of walking ability in children with CLN2 disease, and ALDURAZYME for MPS I, another inherited enzyme deficiency. BioMarin manufactures ALDURAZYME for Sanofi, which sells it worldwide.

The acquisition of Amicus added Galafold for Fabry disease and Pombiliti and Opfolda for Pompe disease. BioMarin has also developed ROCTAVIAN, a gene therapy for severe hemophilia A, but decided to withdraw it from the market. Alongside its marketed medicines, the company researches potential treatments for additional genetic conditions.

How it makes money

2025 total revenue: $3.2 billion; Q2 2026 total revenue: nearly $1 billion.

BioMarin earns most of its revenue by selling prescription medicines. Its commercial organization has been structured around skeletal conditions and enzyme therapies, and it reports one business segment. Revenue depends on patients starting and continuing treatment, as well as the timing of orders from distributors, hospitals and governments. Product sales are recorded net of estimated rebates, discounts and distributor fees, which vary by product and payer.

VIMIZIM generated $792.1 million in 2025 revenue, and NAGLAZYME generated $485.4 million. PALYNZIQ generated $433.3 million, compared with $355.0 million in 2024. VOXZOGO sales increased in 2025 as new patients began treatment across regions. PALYNZIQ sales rose with new patients primarily in the U.S., while KUVAN revenue fell as generic competition increased.

The ALDURAZYME arrangement works differently from most of BioMarin’s product sales. BioMarin manufactures and supplies the medicine to Sanofi and receives payments ranging from 39.5% to 50% of worldwide net ALDURAZYME sales by Sanofi, depending on sales volume. It recognizes estimated revenue when the product is released and control passes to Sanofi.

Some treatments involve continuing administration, including daily VOXZOGO injections and PALYNZIQ injections. Sales are not necessarily even from quarter to quarter: some governments buy through large periodic orders. The Amicus acquisition added commercial medicines to the portfolio, while BioMarin is withdrawing ROCTAVIAN.

Customers and how it sells

BioMarin sells medicines in the U.S., Europe, South America and other international markets. Its own commercial teams promote products to physicians in the specialties relevant to each medicine. In selected markets, outside distributors market products and generally are responsible for securing the necessary local approvals.

Customers other than Sanofi include specialty pharmacies, hospitals, non-U.S. government agencies, authorized distributors and pharmaceutical wholesalers. In 2025, three customers accounted for 37% of net product revenue. Sanofi is the sole customer for ALDURAZYME and handles its global distribution and sales to third parties.

The U.S. distribution channel for PALYNZIQ is restricted to certified specialty pharmacies under a safety program intended to manage the risk of anaphylaxis, a severe allergic reaction. Prescribers and patients must also enroll in the program, and patients must have injectable epinephrine available.

Outside the U.S., some governments place large periodic orders rather than buying on a regular schedule. Their timing can cause revenue to vary between periods. BioMarin also uses outside logistics companies to store and distribute its products.

Suppliers and costs

BioMarin makes active pharmaceutical ingredients for several products at its facilities in Novato, California, and Shanbally, Ireland. The Irish site also has filling and packaging capabilities. The company uses contractors for much of its finished-drug manufacturing and for some active ingredients and packaging.

Certain manufacturing steps have only one approved contract manufacturer. Some raw materials are available from only one supplier or one approved source. BioMarin seeks to reduce disruption by holding safety stock and, where feasible, using multiple sources. Its facilities and contractors are subject to regulatory inspections.

Cost of sales includes raw materials, staff, facilities, contract manufacturing, formulation and packaging, as well as royalties and inventory write-downs. Research and development costs include clinical studies, manufacturing of clinical supplies, staff and regulatory work. Sales and marketing spending supports product promotion and patient services.

The decision to withdraw ROCTAVIAN resulted in approximately $240.0 million of restructuring charges in 2025. BioMarin said interest expense increased in Q2 2026 because of acquisition debt financing, while interest income decreased as investments were sold to fund the Amicus acquisition.

Competitive position

BioMarin competes with other drug developers and manufacturers, including companies pursuing treatments for the same rare diseases. PTC Therapeutics markets an oral treatment for phenylketonuria in the U.S. and EU, competing with PALYNZIQ and KUVAN. Multiple generic versions of KUVAN are also available in those markets.

At year-end 2025, potential VOXZOGO competitors in achondroplasia included clinical-stage products from Ascendis Pharma, QED Therapeutics and other developers. BioMarin subsequently said it faced a U.S. competitor and had seen approximately 10% of patients switch. It said injection fatigue or interest in a weekly therapy were the main reasons it heard for switching.

Other pipeline competition includes RegenxBio candidates in several disease areas and marketed Duchenne muscular dystrophy therapies from Sarepta Therapeutics and others. BioMarin is developing BMN 351 for Duchenne muscular dystrophy.

Our reading: Patents and regulatory exclusivity provide a meaningful but time-limited defense; BioMarin is also pursuing legal actions to protect VOXZOGO patents. Our reading: Existing approvals, manufacturing capabilities and patient relationships support its position, but they do not prevent patients from switching or competitors from developing alternatives.

Growth opportunities

BioMarin’s growth plans include reaching more patients with existing medicines, expanding approved uses and developing or acquiring new treatments. The company attributes 2025 VOXZOGO growth to new patients starting therapy across regions. It has submitted an application to extend VOXZOGO to hypochondroplasia after a Phase 3 study that it said achieved statistical significance on height measures and arm span.

BioMarin estimates a global addressable population of 14,000 patients for hypochondroplasia, assuming continued progress in diagnosis and awareness. It is also developing BMN 333, a longer-acting treatment candidate for growth disorders, and has enrolled patients in its clinical study across multiple countries.

The Amicus acquisition added Galafold and Pombiliti and Opfolda to the commercial portfolio. BioMarin plans to increase diagnosis and treatment of Fabry disease patients and expand the medicines into additional markets. It expects approximately $220 million of annual cost synergies to be fully realized in 2028. BioMarin retained the Amicus commercialization team to support patient continuity.

The acquisition also added BMN820, which is in Phase III development for focal segmental glomerulosclerosis, a kidney disease. BioMarin holds exclusive U.S. commercialization rights and is partnered with Dimerix, which is running the study. Other programs include BMN 401 for ENPP1 deficiency, acquired through Inozyme, and BMN 351 for Duchenne muscular dystrophy.

Structural risks

• Competition and exclusivity: KUVAN faces generic competition, and other companies are developing treatments for BioMarin’s indications. Patents and regulatory exclusivity expire at different times, and competitors may challenge intellectual property or develop alternative products.
• Clinical and regulatory outcomes: Adverse or inconclusive trial results can prevent approval. Slow enrollment, safety issues, insufficient supplies or regulatory requests for further studies can delay or stop trials. Approved products remain subject to safety and manufacturing requirements.
• Manufacturing and supply: Some raw materials and manufacturing steps depend on a single supplier or approved contractor. Supply interruptions or inspection problems can disrupt product availability and delay development.
• Acquisition integration and financing: Combining Amicus with BioMarin may bring unforeseen liabilities, systems issues or difficulties retaining relationships and employees. Acquisition financing increased interest expense and reduced investment balances.
• Orders and international operations: Large government orders can vary in timing, creating revenue fluctuations. Foreign currency movements, economic weakness and geopolitical disruption can also affect sales or customers’ ability to pay.
• Product safety and commercialization: PALYNZIQ’s U.S. safety program restricts distribution and requires patient and prescriber participation. BioMarin decided to withdraw ROCTAVIAN after commercial opportunities were lower than anticipated.

Bottom line

Our reading

BioMarin is a rare-disease drug business built on marketed medicines, specialist commercialization and continued research into genetic conditions. [item1] Its portfolio has expanded through Amicus, but the acquisition also brings integration work and financing costs. [call_prepared; item1a] The business remains exposed to competition, uneven government ordering and the clinical and regulatory risks of developing new uses and medicines. [item1; item1a; item7]